Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (KYMR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,190,950
  • Shares Outstanding, K 54,706
  • Annual Sales, $ 72,830 K
  • Annual Income, $ -100,220 K
  • 60-Month Beta 0.99
  • Price/Sales 16.58
  • Price/Cash Flow N/A
  • Price/Book 2.87
Trade KYMR with:

Options Overview Details

View History
  • Implied Volatility 98.38% ( +0.98%)
  • Historical Volatility 75.69%
  • IV Percentile 83%
  • IV Rank 57.49%
  • IV High 131.11% on 05/19/22
  • IV Low 54.12% on 11/12/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 3,176
  • Open Int (30-Day) 3,335

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.69
  • Number of Estimates 11
  • High Estimate -0.42
  • Low Estimate -0.89
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -23.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.81 +4.61%
on 09/26/22
29.88 -27.14%
on 09/09/22
-6.35 (-22.58%)
since 08/30/22
3-Month
18.90 +15.19%
on 07/01/22
35.19 -38.14%
on 08/24/22
+2.08 (+10.56%)
since 06/30/22
52-Week
13.15 +65.55%
on 06/16/22
69.12 -68.50%
on 11/08/21
-36.97 (-62.94%)
since 09/30/21

Most Recent Stories

More News
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -14.71% and 9.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 21.77 (-1.36%)
IMRX : 14.32 (+9.15%)
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated...

KYMR : 21.77 (-1.36%)
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 80% and 20.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 20.03 (+1.16%)
KYMR : 21.77 (-1.36%)
Will Humanigen Inc. (HGEN) Report Negative Q2 Earnings? What You Should Know

Humanigen Inc. (HGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HGEN : 0.1800 (+7.78%)
KYMR : 21.77 (-1.36%)
Myriad Genetics (MYGN) Q2 Earnings and Revenues Top Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MYGN : 19.08 (-2.20%)
KYMR : 21.77 (-1.36%)
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -46.15% and 3.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 23.20 (-2.32%)
KYMR : 21.77 (-1.36%)
Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KYMR : 21.77 (-1.36%)
PLRX : 20.89 (+0.63%)
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

KYMR : 21.77 (-1.36%)
4 Downgraded Stocks You'll Want to Sell or Avoid Right Now

With the growing odds of the economy tipping into a recession due to an aggressive monetary policy tightening to tame the sky-high inflation, it could be difficult for fundamentally weak stocks to stay...

IVZ : 13.70 (-3.04%)
KYMR : 21.77 (-1.36%)
MOGO : 0.9200 (+0.01%)
SANA : 6.00 (+7.53%)
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing...

KYMR : 21.77 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.

See More

Key Turning Points

3rd Resistance Point 24.34
2nd Resistance Point 23.81
1st Resistance Point 22.79
Last Price 21.77
1st Support Level 21.24
2nd Support Level 20.70
3rd Support Level 19.68

See More

52-Week High 69.12
Fibonacci 61.8% 47.74
Fibonacci 50% 41.14
Fibonacci 38.2% 34.53
Last Price 21.77
52-Week Low 13.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar